Beyond development: Using continuous manufacturing to accelerate OSD commercialization

For oral solid dose (OSD) therapies approaching commercialization, the integration of continuous processes and Real-Time Release Testing (RTRT) offers clear advantages in speed, quality, and scalability.

This webinar goes beyond the technical ‘how’ to explore the strategic ‘why’, featuring expert insights into the practical and regulatory realities of scaling continuous manufacturing for commercial use. Our speakers will share firsthand insights from supporting a recently filed OSD product – Thermo Fisher’s first OSD product supported by RTRT and submitted across major global markets, including the U.S. and EU– and discuss how continuous manufacturing can be leveraged to streamline your path from late-phase development through commercial launch.

Key takeaways:

• Learn how continuous manufacturing and RTRT enabled a successful regulatory submission for a commercial OSD therapy.
• Understand how this approach can accelerate timelines, enhance quality, and reduce scale-up complexity.
• The strategic advantages of integrating RTRT and continuous processes from the outset
• Gain practical insights from Phase III through commercial launch to inform your own development strategy.